
**PL01. Plenary Nobel Laureate Lecture:
A half-century of neurotransmitter
research: impact on neurology and
psychiatry**

Introduction by: Göran Sedvall (S)

PL01

A half-century of neurotransmitter research: impact on neurology and psychiatry

A. Carlsson*. *Department of Pharmacology, University of Gothenburg and Carlsson Research AB, Gothenburg, Sweden*

This lecture will review some salient features of the work by me and my colleagues on dopamine and serotonin, starting with the discovery of dopamine as an agonist in its own right in the 1950s and of its role in important brain functions. It will then describe the resistance to our views met with by leading authorities in the field and our continued efforts that led to general acceptance of the monoamines' neurotransmitter role in the CNS. This meant a true paradigm shift with wide implications for basic research as well as for the understanding and treatment of a variety of mental and neurological disorders.

A final section the lecture will deal with dopaminergic stabilization as a novel therapeutic principle. It will be argued that this principle has important advantages in comparison to treatments using straight-forward receptor agonism or antagonism. Preliminary clinical observations tend to confirm our theoretical considerations.

**LS01. Schizophrenia
(Sponsored by Eli Lilly)**

Chair: R.M. Murray (GB)

LS01.1

Welcome and opening remarks

R.M. Murray. *UK*

No abstract was available at the time of printing.

LS01.2

Neuroplasticity

M. Spitzer. *Germany*

No abstract was available at the time of printing.

LS01.3

Acute psychosis in clinical setting

A. Young. *UK*

No abstract was available at the time of printing.

LS01.4

Acute agitation: new treatments

P. Wright. *UK*

No abstract was available at the time of printing.

LS01.5

Compliance, cognition and psychosis: first episode

R. Keefe. *USA*

No abstract was available at the time of printing.

LS01.6

Acute treatment in Eastern Europe

N. Sartorius. *Switzerland*

No abstract was available at the time of printing.

LS01.7

Quality of life and health outcomes: what really matters

M. Knapp. *UK*

No abstract was available at the time of printing.

**LS02. Achieving success in schizophrenia:
cognition, control & compliance**

Chair: R.M. Murray (GB)

LS02.1

Chairman's address: Novel treatments – a promise fulfilled?

R.M. Murray. *UK*

No abstract was available at the time of printing.

LS02.2

Exploring cognition and frontal lobe disorders

R.J. van den Bosch. *The Netherlands*

No abstract was available at the time of printing.

LS02.3

Taking the patient's view

A. Berntsson. *Sweden*

No abstract was available at the time of printing.